Sandbox:Preeti: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
Preeti Singh (talk | contribs) No edit summary |
||
Line 65: | Line 65: | ||
! colspan="24" align="left" style="background:#4479BA; color: #FFFFFF;" + |NHL | ! colspan="24" align="left" style="background:#4479BA; color: #FFFFFF;" + |NHL | ||
|- | |- | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma | ! rowspan="12" align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |B-lymphoblastic leukemia/lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |B-lymphoblastic leukemia/lymphoma | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 80: | Line 80: | ||
* Ionizing radiation | * Ionizing radiation | ||
* Chemotherapy | * Chemotherapy | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
| align="center" style="background:#F5F5F5;" + |– | | align="center" style="background:#F5F5F5;" + |– | ||
Line 104: | Line 104: | ||
* Down syndrome | * Down syndrome | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Follicular lymphoma]] | ! colspan="2" align="center" style="background:#DCDCDC;" + |[[Follicular lymphoma]] | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 153: | Line 152: | ||
* Peripheral nerve compression | * Peripheral nerve compression | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Mantle cell lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Mantle cell lymphoma | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 195: | Line 193: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Diffuse large B cell lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Diffuse large B cell lymphoma | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 238: | Line 235: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | ! colspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Disease | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ||
Line 262: | Line 258: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Burkitt lymphoma]] | ! colspan="2" align="center" style="background:#DCDCDC;" + |[[Burkitt lymphoma]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 309: | Line 304: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |B cell chronic lymphocytic leukemia/small lymphocytic lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |B cell chronic lymphocytic leukemia/small lymphocytic lymphoma | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 334: | Line 328: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="3" align="center" style="background:#DCDCDC;" + |Marginal zone lymphoma | ! rowspan="3" align="center" style="background:#DCDCDC;" + |Marginal zone lymphoma | ||
! align="center" style="background:#DCDCDC;" + |Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type | ! align="center" style="background:#DCDCDC;" + |Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type | ||
Line 360: | Line 353: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |[[Splenic marginal zone lymphoma]] | ! align="center" style="background:#DCDCDC;" + |[[Splenic marginal zone lymphoma]] | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 394: | Line 386: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |[[Nodal marginal zone B-cell lymphoma]] | ! align="center" style="background:#DCDCDC;" + |[[Nodal marginal zone B-cell lymphoma]] | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 430: | Line 421: | ||
* Sjögren syndrome | * Sjögren syndrome | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia) | ! colspan="2" align="center" style="background:#DCDCDC;" + |Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia) | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 455: | Line 445: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |[[Hairy cell leukemia]] | ! colspan="2" align="center" style="background:#DCDCDC;" + |[[Hairy cell leukemia]] | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 511: | Line 500: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
| | | rowspan="10" |T cell lymphoma | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Precursor T-cell lymphoblastic leukemia/lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Precursor T-cell lymphoblastic leukemia/lymphoma | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 536: | Line 525: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 561: | Line 549: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 586: | Line 573: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Cutaneous T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Cutaneous T-cell lymphoma | ||
! align="center" style="background:#DCDCDC;" + |[[Mycosis fungoides]] / [[Sézary syndrome]] | ! align="center" style="background:#DCDCDC;" + |[[Mycosis fungoides]] / [[Sézary syndrome]] | ||
Line 625: | Line 611: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! rowspan="6" align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma | ! rowspan="6" align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma | ||
! align="center" style="background:#DCDCDC;" + |Subcutaneous panniculitis-like T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Subcutaneous panniculitis-like T-cell lymphoma | ||
Line 651: | Line 636: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Hepatosplenic gamma-delta T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Hepatosplenic gamma-delta T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 676: | Line 660: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Enteropathy-type intestinal T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Enteropathy-type intestinal T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 701: | Line 684: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Extranodal T-cell lymphoma, nasal type | ! align="center" style="background:#DCDCDC;" + |Extranodal T-cell lymphoma, nasal type | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 726: | Line 708: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Angioimmunoblastic T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Angioimmunoblastic T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 751: | Line 732: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma, unspecified | ! align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma, unspecified | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | |
Revision as of 16:02, 17 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]
Category | Disease | Etiology | Clinical manifestations | Paraclinical findings | Gold standard | Associated findings | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lab findings | |||||||||||||||||||||||
Demography | History | Symptoms | Signs | CBC | PBS | PT/PTT | Immunochemistry | Histopathology | Other | ||||||||||||||
Constitutional symptoms | Rash | Abdominal pain | Diarrhea | V/S | Mass | Hepatosplenomegaly | Other | WBC | Hb | Plt | |||||||||||||
HL | |||||||||||||||||||||||
Hodgkin's Lymphoma | |||||||||||||||||||||||
NHL | |||||||||||||||||||||||
B Cell Lymphoma | B-lymphoblastic leukemia/lymphoma |
|
|
|
+ | – | – | – |
|
± |
|
↓ | ↓ | Nl to ↓ |
| ||||||||
Follicular lymphoma |
|
|
|
Only in 20% of patients: | + | + | ± | Nl |
|
+ | ↓ | ↓ | Nl to ↓ |
|
NA |
|
|
|
Lymph node biopsy |
| |||
Mantle cell lymphoma |
|
|
Abdominal distention |
|
+ |
|
|
↓ | Nl to ↓ |
|
|
|
|||||||||||
Diffuse large B cell lymphoma |
|
|
|
↓ | ↓ | Nl to ↓ |
|
Centroblastic
Immunoblastic
Anaplastic
|
|
||||||||||||||
Disease | Etiology | Demography | History | Constitutional symptoms | Rash | Abdominal pain | Diarrhea | V/S | Mass | Hepatosplenomegaly | Other | WBC | Hb | Plt | PBS | PT/PTT | Immunochemistry | Histopathology | Other lab findings | Gold standard | Associated findings | ||
Burkitt lymphoma |
|
|
|
|
|||||||||||||||||||
B cell chronic lymphocytic leukemia/small lymphocytic lymphoma |
|
||||||||||||||||||||||
Marginal zone lymphoma | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type |
|
|||||||||||||||||||||
Splenic marginal zone lymphoma |
|
|
|||||||||||||||||||||
Nodal marginal zone B-cell lymphoma |
|
+ |
|
|
|
| |||||||||||||||||
Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia) |
|
||||||||||||||||||||||
Hairy cell leukemia |
|
|
|
||||||||||||||||||||
T cell lymphoma | Precursor T-cell lymphoblastic leukemia/lymphoma |
|
|||||||||||||||||||||
Adult T cell leukemia/lymphoma |
|
||||||||||||||||||||||
Anaplastic large cell lymphoma |
|
||||||||||||||||||||||
Cutaneous T-cell lymphoma | Mycosis fungoides / Sézary syndrome |
|
|
|
|||||||||||||||||||
Peripheral T-cell lymphoma | Subcutaneous panniculitis-like T-cell lymphoma |
|
|||||||||||||||||||||
Hepatosplenic gamma-delta T-cell lymphoma |
|
||||||||||||||||||||||
Enteropathy-type intestinal T-cell lymphoma |
|
||||||||||||||||||||||
Extranodal T-cell lymphoma, nasal type |
|
||||||||||||||||||||||
Angioimmunoblastic T-cell lymphoma |
|
||||||||||||||||||||||
Peripheral T-cell lymphoma, unspecified |
|